40 results about "Breast cancer chemotherapy" patented technology

The invention discloses an application of a cordyceps militaris link extract to preparation of a health-care product or a medicament for prompting leucocyte proliferation of a breast cancer patient. In an extracting method of the cordyceps militaris link extract, water or an ethanol solution is adopted for extracting cordyceps militaris link. As proved by clinical test of a breast cancer chemotherapy patient, the extract has a good effect on prompting the leucocyte proliferation of the chemotherapy patient, and can be used for preparing a health-care food or a medicament for assisting in treating tumors. The invention discloses a novel clinical application of cordyceps militaris link after increase of leucocytes after chemotherapy on the breast cancer patient. The cordyceps militaris link extract plays a positive role in comprehensively utilizing and developing cordyceps militaris link.

Method for the prediction of the response to epirubicin/cyclophosphamide-based chemotherapy of a breast cancer in a patient, from a tumour sample of said patient, comprising steps of determining the expression level of a group of marker genes consisting of (i) a first marker gene selected from the group consisting of MLPH, SPDEF, and AKR7A3; and (ii) a pair of second marker genes selected from the group of pairs consisting of (H2BFS and UBE2S), (BGN and ZBTB16), (ZBTB16 and EMP1), (LGALS8 and UBE2S) and (OLFML2B and ZBTB16); and (iii) a third marker gene selected from the group consisting of CYBA, ACP5, a gene specifically binding to Affymetrix probe set ID 210915 x at, LCK, GSTM3; classifying said sample as belonging to one of several breast cancer response classes from the expression levels determined; predicting the response of said breast cancer in said patient to chemotherapy from previously known characteristic properties of tumours of said one of several breast cancer response classes.

The invention provides an application of miR-218 in preparing a breast cancer chemotherapeutic drug sensitizer, and belongs to the technical field of molecular drugs of breast cancer. According to theapplication of miR-218 in preparing the breast cancer chemotherapeutic drug sensitizer, miR-218 can obviously increase the sensitivity of breast cancer cells to paclitaxel and doxorubicin; in addition, miR218 can target down-regulate the expression of a DAAM1 gene, and inhibit the proliferation and invasion capacity of breast cancer cells by target down-regulating the expression of the DAAM1 gene. Therefore, a nucleic acid sequence is used as a novel small nucleic acid anti-tumor medicament, so that the sensitivity of breast cancer to chemotherapy medicaments can be enhanced, the proliferation and invasion of tumors can be inhibited, and the nucleic acid sequence has a good application prospect.

The invention provides a long non-coding RNA gene marker for diagnosing breast cancer chemotherapy-related myocardial injury. The long non-coding RNA is LINC01471. Through the discovery of the screening of a chip technology, compared with breast cancer patients before chemotherapy, the expression of the LINC01471 can be significantly enhanced in the blood of the patients with myocardial injury after the chemotherapy, and results can be further verified in fluorescence quantitation PCR. The beneficial effects are as follows: a molecular marker for diagnosing the breast cancer chemotherapy-related myocardial injury is provided; and whether the breast cancer patients have myocardial injury can be judged at the early stage of the chemotherapy by detecting the molecular marker, so that corresponding treatment measures can be taken as early as possible, and the possibility of the myocardial injury occurring in the breast cancer patients during treatment can be decreased. Compared with biochemical markers, the provided lncRNA marker has the characteristics of being high in sensitivity and strong in specificity.

The invention discloses a tumor suppressor gene NDRG2 based application for improving breast cancer chemotherapy sensibility. The tumor suppressor gene NDRG2 is transfected into a breast cancer cell through an expression vector or a virus vector, and the result shows that the tumor suppressor gene NDRG2 can improve the breast cancer chemotherapy sensibility and can be applied to preparation of relevant drugs. The NDRG2 prompts a deoxyribonucleic acid (DNA) damage ability of Adr induced p53 wild type breast cancer cells, improves morphology damage of Adr to p53 wild type breast cancer cells, improves a proliferation inhibiting ability of the Adr to the p53 wild type breast cancer cells, improves the breast cancer chemotherapy sensibility which is independent of specific chemotherapy drugs and further prompts apoptosis of the Adr induced p53 wild type breast cancer cells.

The invention provides a marker for evaluating breast carcinoma chemotherapeutic effect based on seroglycoid glycoform and an application of the marker. By detecting an expression level of a sugar chain identified by any one or any combination of lectin LCA, GSL-II, GSL-I, PHA-E+L, WFA and RCA120, whether chemotherapy has a curative effect on a patient subjected to breast cancer chemotherapy or not can be evaluated. The specific basis can be referred to as follows: down regulation is performed on the GSL-II, and a down-regulated Fold-change value is between 0.5 and 1.9; the LCA, the GSL-I andthe RCA120 are up-regulated, and an up-regulated Fold-change value is between 1.68 and 2.4, between 3 and 12.5, and between 0.67 and 2.61; and if PHA-E+L and WFA have no significant difference from ahealthy female control group, then the situation indicates that a curative effect is achieved.

The invention discloses an acupoint patch capable of strengthening the spleen and stomach and a preparation method of the acupoint patch and relates to the technical field of traditional Chinese medicine patches. The acupoint patch is prepared from traditional Chinese medicines including fructus perillae, fructus evodiae, rhizoma pinelliae, pericarpium citri reticulatae, fructus schisandrae, caulis polygoni multiflori and semen ziziphi spinosae. The preparation method of the acupoint patch comprises the following steps: (1) weighing all the raw materials in parts by weight; (2) grinding the fructus perillae, the fructus evodiae, the rhizoma pinelliae, the pericarpium citri reticulatae, the fructus schisandrae, the caulis polygoni multiflori and the semen ziziphi spinosae into powder; (3) squeezing fresh ginger to obtain fresh ginger juice; (4) uniformly stirring the powder in step (2) with the fresh ginger juice in step (3) and water according to the weight proportion of 100 to (1 to 10) to (30 to 50); uniformly coating stirred medicine paste in a medical patch groove to obtain the acupoint patch. The acupoint patch disclosed by the invention has simple components, but also has a remarkable medicinal effect; effective components can be completely absorbed through skin pores and the acceptability of patients is strong. When the application time is long, no allergic phenomenon occurs and medicines remained on skins are easy to wash; the attachment property is strong. The acupoint patch disclosed by the invention is used for treating gastrointestinal reaction caused by breastcancer chemotherapy; the immunity is improved, the clinical effect is remarkable and the acupoint patch is worthy of being affirmed.

The invention discloses an analytic kit for breast cancer chemotherapy. The kit comprises a flow cytometry detection kit, a tissue immunohistochemical detection kit and a real-time fluorescent quantitative PCR detection kit, wherein the flow cytometry detection kit is used for counting the number of cells of a clinical tissue sample after chemotherapy of a breast cancer patient to obtain a first drug resistance assessment coefficient of the breast cancer patient after chemotherapy; the tissue immunohistochemical detection kit is used for performing double staining on the clinical tissue sampleto obtain a second drug resistance assessment coefficient of the breast cancer patient after chemotherapy; performing quantitative amplification for the clinical tissue sample with a real-time fluorescent quantitative PCR detection kit to obtain a third drug resistance assessment coefficient of the breast cancer patient after chemotherapy; and calculating the drug resistance index of the breast cancer patient after chemotherapy through the first drug resistance assessment coefficient, the second drug resistance assessment coefficient and the third drug resistance assessment coefficient. By adopting the method, the product support is provided for comprehensive and complement assessment on the drug resistance situation of the breast cancer patient after chemotherapy.

The invention relates to a medicine delivery system for combined precise treatment of breast cancer and application thereof. Ferroferric oxide is used as a magnetic ligand; meso-porous silicon-graphene nano-sheets are used as basic carriers; medicine delivery carriers are obtained through hydrophilic polymers of polyethylene glycol; the medicine delivery carriers and an insoluble micromolecular chemotherapeutic medicine of adriamycin form a meso-porous silicon-graphene nano-sheet-ferroferric oxide-polyethylene glycol/adriamycin medicine delivery system. The system can be used for the combinedprecise treatment (combining chemotherapy and photothermal therapy) of the breast cancer; the death rate of the breast cancer cells can be obviously improved. Compared with the medicine delivery system built by the prior art, the medicine delivery system has the advantages that various advantages are integrated; the combined targeted treatment of the breast cancer chemotherapy and photothermal therapy can be realized; the toxic and side effects of the whole body can be reduced; the repeated and complicated medicine delivery can be avoided through good medicine release features; the complianceof patients is improved.

The invention relates to two single-nucleotide polymorphism (SNP) sites rs2420946 and rs2981578 associated with a breast cancer on a fibroblast growth factor receptor (FGFR) gene for predicting breast cancer chemotherapy toxicity. Through development and application of an SNP biomarker and a breast cancer chemotherapy toxicity diagnosis kit, the toxicity reaction degree after breast cancer chemotherapy is predicted, thereby guiding medication for tumor chemotherapy and providing a new way for a clinical doctor for predicting prognosis of a patient.

The invention relates to a chemotherapy composition, a preparation method thereof and breast cancer chemotherapy application thereof. The composition is characterized in that the toxicity is small, the anti-cancer activity is high, the composition is mainly composed of a ginsenoside component, a ginseng polysugar component and ifosfamide according to a certain ratio, and the weight ratio is (1-10):(1-10):(1-10). Compared with ifosfamide, the composition has higher anti-cancer activity on experimental breast cancer mice and is almost free of adverse reactions such as myelosuppression.

The invention relates to a marker and a model for predicting chemotherapy response of triple negative breast cancer. The marker comprises one or a combination of more than two of the following genes: AKT2, ARG1, BIRC7, CCR3, CDKN2A, CHGB, CNN1, CYP7A1, FGF5, KMT2A, NME1, NRAS, PCP4, PRC1, PRKCI, SUZ12, VEGFC, WRN and ZBTB16. According to the method, the chemotherapy response is taken as a target function, and the accurate model for predicting the chemotherapy response of the triple-negative breast cancer is established by utilizing the whole transcriptome data of the triple-negative breast cancer slice based on an iterative linear regression algorithm of correlation coefficient layering. By utilizing the model, evaluation can be performed before chemotherapy of a triple-negative breast cancer patient, and the model is used for guiding establishment of a treatment scheme.

The present invention provides use of Tadalafil as a protein arginine methyltransferase 5 (PRMT5) inhibitor. The present invention finds out that Tadalafil is a PRMT5 inhibitor by virtually screening active compounds targeting PRMT5 based on crystal structure and information about active sites of PRMT5. The present invention not only confirms that Tadalafil can inhibit an enzymatic activity of PRMT5, but also confirms that Tadalafil alone can inhibit tumor growth in breast cancer and improve sensitivity to chemotherapy for breast cancer.

The invention provides a compound taxus chinensis capsule, a preparation method and application of the compound taxus chinensis capsule for treating qi deficiency and phlegm stasis in breast cancer chemotherapy. Wherein the compound taxus chinensis capsule is prepared by mixing a taxus chinensis extract, a red ginseng extract and a liquorice extract. The preparation method adopts a supercritical extraction method. Technical improvement is carried out on the basis of an existing variety, and the technically improved compound taxus chinensis capsule has remarkable activity in maintenance treatment of stable recurrence rejection and/or metastatic advanced triple-negative breast cancer after first-line chemotherapy for 6-8 cycles and drug resistance (qi deficiency and phlegm stasis) of endocrine treatment with positive hormone receptors, and the existing technical blank is filled.